Featured
April 28, 2026
ASAP and MJFF announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.
Read More
This blog discusses how ASAP's latest investment aims to accelerate medical breakthroughs by creating a global, open-science toolkit of standardized resources and tools to overcome existing research barriers to overcome existing research barriers.
Read More
The Guardian reports on a breakthrough study by CRN Team Schapira, which identified a distinct gut microbial "signature" that can signal Parkinson's risk years before physical symptoms appear.
View Story
ASAP and MJFF announced $261 million in new grant funding for the Collaborative Research Network (CRN) to map the biological blueprint of Parkinson’s disease and build a standardized toolkit of global research resources that are needed to turn discoveries into treatments.
Read More
ASAP is proud to showcase the inaugural cohort of Discovery Fellows. Learn more about the funded projects!
Read More
In this edition of the ASAP Research Round-Up, ASAP presents Q1 2026 highlights from across its portfolio, showcasing efforts to advance Parkinson’s discovery, facilitate the rapid global exchange of ideas, broaden open-science accessibility, and support the next generation of Parkinson’s researchers.
Read More
On genomics podcast Mendelspod, Andy Singleton, co-lead of the Global Parkinson's Genetics Program (GP2), and Nacho Mata, Cleveland Clinic geneticist and LARGE-PD founder, discuss how GP2 is accelerating discovery and expanding global representation in Parkinson’s research.
View Story
Reports that the College of Medicine, University of Lagos (CMUL) commissioned the GP2–CMUL Molecular Laboratory to strengthen Parkinson’s disease research, genomics capacity, and training opportunities across Africa in collaboration with Aligning Science Across Parkinson’s (ASAP) and the Global Parkinson’s Genetics Program (GP2).
Read More
We are proud to share how we impacted the Parkinson’s disease research field in 2025. Read our report to see how the infrastructure and processes we established are changing the way science is done and are generating significant momentum.
Read More
Researchers have reached a major milestone in the effort to understand and treat Parkinson’s disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson’s Genetics Program (GP2).
Read More
